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Abstract
Background: The neglected tropical disease Buruli ulcer (BU) caused by Mycobacterium ulcerans is an infection of the
subcutaneous tissue leading to chronic ulcerative skin lesions. Histopathological features are progressive tissue necrosis,
extracellular clusters of acid fast bacilli (AFB) and poor inflammatory responses at the site of infection. After the
recommended eight weeks standard treatment with rifampicin and streptomycin, a reversal of the local immunosuppres-
sion caused by the macrolide toxin mycolactone of M. ulcerans is observed.
Methodology/Principal Findings: We have conducted a detailed histopathological and immunohistochemical analysis of
tissue specimens from two patients developing multiple new skin lesions 12 to 409 days after completion of antibiotic
treatment. Lesions exhibited characteristic histopathological hallmarks of Buruli ulcer and AFB with degenerated
appearance were found in several of them. However, other than in active disease, lesions contained massive leukocyte
infiltrates including large B-cell clusters, as typically found in cured lesions.
Conclusion/Significance: Our histopathological findings demonstrate that the skin lesions emerging several months after
completion of antibiotic treatment were associated with M. ulcerans infection. During antibiotic therapy of Buruli ulcer
development of new skin lesions may be caused by immune response-mediated paradoxical reactions. These seem to be
triggered by mycobacterial antigens and immunostimulators released from clinically unrecognized bacterial foci. However,
in particular the lesions that appeared more than one year after completion of antibiotic treatment may have been
associated with new infection foci resolved by immune responses primed by the successful treatment of the initial lesion.
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Introduction
Buruli ulcer (BU) is a chronic necrotizing infection of
subcutaneous tissue caused by Mycobacterium ulcerans [1-4]. BU
seems to start usually as a movable subcutaneous nodule or papule
and may later progress to a plaque or edema. After destruction of
subcutaneous tissue, the skin may break down centrally leading to
the development of largely painless necrotic skin ulcers with
characteristic undermined edges. These may progress to large
necrotic lesions. M. ulcerans is unique among mycobacterial
pathogens in that it resides in advanced lesions mainly extracel-
lularly. A histopathological hallmark of progressing BU is a poor
local inflammatory response in the presence of clusters of
extracellular acid-fast bacilli surrounded by areas of necrosis [5–
7]. M. ulcerans produces a toxin with a polyketide-derived
macrolide structure, named mycolactone, which plays a central
role in tissue destruction and local immunosuppression. Observa-
tions both in cell culture and infection models indicate that cells
infiltrating BU lesions are killed due to the cytotoxic and apoptosis
inducing activity of mycolactone [7–10]. While M. ulcerans may be
captured by phagocytes during initial stages of infection, it appears
to persist only transiently inside these host cells [11,12]. After
killing of the phagocytes, extracellular growth leads to the
development of extracellular mycolactone-producing bacterial foci
in areas of coagulating necrosis. Thermosensitivity of M. ulcerans
seems to favor development of skin lesions of the limbs [13–15].
Clinical diagnosis of BU can be confirmed by insertion sequence
2404 (IS2404) PCR [16–18], microscopic detection of acid-fast
bacilli (AFB), culture of M. ulcerans [19] and histopathological
examination of lesions [6,20–22]. While surgery has traditionally
been the only recommended treatment for BU [23,24], WHO
recommends currently as a first-line treatment a combination
therapy with rifampicin and streptomycin (R/S) for eight weeks for
all forms of the active disease [25,26]. After a pilot study assessing
www.plosntds.org 1 August 2011 | Volume 5 | Issue 8 | e1252treatment of BU with R/S [25], a case-series in Benin showed that
of 224 patients 215 were successfully treated [27], with 47% of
them receiving antibiotics only. More recently, studies by Nienhuis
et al., Kibadi et al. and Sarfo et al. [28–30] reconfirmed efficacy of
R/S treatment. However, de ´bridement, surgery and skin grafting
may be used as an adjunct to the antimicrobial therapy, mainly to
remove necrotic tissue, cover skin defects and correct deformities.
Reported rates of recurrence after surgical treatment alone
range between 6% and 47% because even wide surgical excision of
lesions may not remove all bacilli [31–34]. Recurrences may be
caused by small numbers of M. ulcerans that have spread to healthy
tissue surrounding the primary lesion [5]. Also lymphohemato-
genous spread of the mycobacteria may occur, since subsets of BU
patients develop multiple skin lesions or metastatic osteomyelitis
[35–39]. Although clinical trials indicate that some bacilli may
survive the recommended eight week course of antibiotic
treatment [28,30], recurrence rates after R/S treatment are as
low as 1–2% [27,29].
In active BU disease, a protective cloud of mycolactone around
the mycobacterial clusters is thought to both destroy infiltrating
leukocytes and hinder them from passing pro-inflammatory signals
to other cells. It is most likely, but still remains to be formally
proven, that mycolactone production is reduced or abolished early
after the onset of R/S chemotherapy due to impairment of
mycolactone synthesis, bacterial growth arrest and/or bacterial
cell death, reflected by ‘beaded’ appearance of AFBs (MT Ruf;
unpublished results). Declining toxin levels allow leukocytes to
reach the extracellular mycobacteria, leading to their phagocytosis
and destruction [40]. Chronic leukocyte infiltration cumulates in
the development of ectopic lymphoid structures [20]. After eight
weeks of R/S chemotherapy, antigen presenting cells as well as B
and T lymphocyte foci are found in large numbers inside the BU
lesions [20] indicating that antigen recognition and processing is
leading to active M. ulcerans specific immune responses. Vigorous
local immune responses during R/S treatment may lead in some
of the patients to the development of clinical deteriorations,
‘paradoxical reactions’ [41]. For this study we conducted detailed
immunohistochemical analyses of secondary lesions which had
occurred at extended periods of time after effective R/S treatment
at different body sites.
Materials and Methods
Ethics statement
Ethical approval for analyzing patient specimens was obtained
from the ethical review board of the Ministry of Health of Benin.
Written informed consent from the guardians of the patients was
obtained before surgical specimens were used for reconfirmation
of BU as well as a detailed immunohistological analysis.
Study participants
Both patients, two six year old boys, included in this study were
laboratory-confirmed BU cases with one primary lesion. Both
received a combination of rifampicin (10 mg/kg body weight) and
streptomycin (15 mg/kg body weight) administered daily over 8
weeks at the Centre de Diagnostic et de Traitement de l’Ulce `re de
Buruli (CDTUB) in Pobe `, Benin according to the WHO
recommendations. Both patients developed several new lesions
at different parts of the body, 12 – 409 days after completion of
antibiotic treatment. These lesions were removed by limited
excision and no additional antibiotic treatment was administered.
Excised tissue from a number of these new lesions became
available for histopathological analysis (Table 1). Both patients
were tested negative for HIV, shistosomiasis, hepatitis B and
syphilis. Blood values tested and the nutritional status was within
the limits typically found in children in rural Africa. Only patient 2
presented with a BCG scar.
Histopathological analysis
Tissue specimens analyzed are listed in Table 1. Samples were
fixed in 4% neutral-buffered paraformaldehyde for 24 h and
subsequently transferred to 70% ethanol for storage and transport.
Afterwards biopsies were dehydrated, embedded in paraffin, and
cut into 5 mm thin sections. After deparaffinization and rehydra-
tion sections were either directly stained with haematoxylin/eosin
(HE) or Ziehl-Neelsen/methylenblue (ZN) according to WHO
standard protocols [42] or further processed for immunohisto-
chemistry (IHC). For IHC antigen retrieval was performed
according to standard protocols either with citrate buffer, EDTA
buffer or by enzymatic trypsin digestion (DakoH Education guide:
Immunohistochemical Staining methods). Afterwards endogenous
peroxidase was inactivated with 0.3% H202 for 20 min and
prevention of unspecific binding was achieved by incubation with
blocking serum matching the secondary antibody host. Primary
antibodies specific for N-Elastase (polymorphonuclear neutrophils
[PMNs]; Dako clone NP57), CD3 (T-lymphocytes; Dako clone
F7.2.38), CD8 (CD8
+ T-lymphocytes; Serotec clone 4B11), CD14
(Monocytes/macrophages; Novocastra clone 7) and CD20 (B-
lymphocytes; Novocastra clone7D1) were appropriately diluted in
phosphate buffered saline (PBS) containing 0.1% Tween-20 and
added to the slides for 1 h at room temperature or over night at
4uC. After incubation with a matching biotin-conjugated second-
ary antibody staining was performed using the Vector NovaRED
system. Haematoxylin was used as a counter stain.
Results
Clinical presentation of BU patients developing
secondary skin lesions after completion of antibiotic
treatment
In the present report we describe clinical and histopathological
observations in two BU patients that have developed series of new
skin lesions (Table 1) after effective anti-mycobacterial chemo-
therapy.
Author Summary
Buruli ulcer (BU) is a chronic necrotizing skin disease
presenting with extensive tissue destruction and local
immunosuppression. Standard treatment recommended
by the WHO includes 8 weeks of rifampicin/streptomycin
and, if necessary, wound debridement and skin grafting. In
some patients satellite lesions develop close to the primary
lesion or occasionally also at distant sites during effective
antibiotic treatment of the primary lesion. We performed a
detailed analysis of tissue specimens from lesions that
emerged in two BU patients from Benin 12 to 409 days
after completion of chemotherapy. Histopathology re-
vealed features of tissue destruction typically seen in BU
and degenerated acid-fast bacilli. In addition, lesions
contained organized immune infiltrates typically found in
successfully treated BU lesions. Secondary lesions emerg-
ing many months after completion of chemotherapy may
have been caused by immune response-mediated para-
doxical reactions. However, the late onset may also
indicate that they were associated with new infection foci
spontaneously resolved by adaptive immune responses
primed by antibiotic treatment of the primary lesions.
Chemotherapy of Buruli Ulcer
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Diagnostic et de Traitement de l’Ulce `re de Buruli (CDTUB) in
Pobe `, Benin with a 15615 cm ulcerated plaque lesion at the right
forearm and elbow with undermined edges characteristic for BU
(Figure 1A). First BU symptoms had been noticed eight month
before and the lesion had been treated afterwards with traditional
medication. After admission to the hospital clinical diagnosis was
confirmed by a positive IS2404 PCR result of a fine needle
aspirate, whereas culture was negative. As recommended in the
WHO guidance on the role of specific antibiotics in the
management of BU [26] the patient received for 8 weeks daily
oral rifampicin (10 mg/kg body weight) and intramuscular
Table 1. Features of skin lesions that emerged after completion of antibiotic treatment.
Patient Primary lesion
Time span (days) between
completion of antibiotic
treatment and occurrence
of secondary lesion
Time span (days)
between occurrence
of secondary lesion
and surgical excision
Nature of
satellite lesion
Location of
satellite lesion
Distance of
satellite from
primary lesion
1 ulcer at the right
upper arm/elbow
75 4 ulcer 1 right axilla 10 cm
275 1 nodule 1 back 25 cm
409 2 ulcer 2 right shoulder 20 cm
409 2 nodule 2 thorax 30 cm
2 ulcer at the right
upper leg/knee
12 6 nodule 1 right upper leg 5 cm
46 33 nodule 2 right lower leg 15 cm
54 25 nodule 3 right upper leg 5 cm
176 1 nodule 4 right foot 30 cm
Lesions from which tissue samples became available for histopathological analysis are written in bold letters.
doi:10.1371/journal.pntd.0001252.t001
Figure 1. Clinical presentation of lesions (Patient 1). A: Initial ulcerated lesion at the right arm, reaching from the elbow to the forearm. B:
Nodule1 appearing on the back, 275 days after end of antibiotic treatment. Both, nodule 2 on the thorax (C) and an ulcerated plaque on the right
shoulder (D) had appeared 409 days after completion of antibiotic treatment.
doi:10.1371/journal.pntd.0001252.g001
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this standard R/S chemotherapy wound de ´bridement was
performed, 18 days after the last excision skin grafting was done
and 83 days after grafting the primary lesion had healed.
75 days after completion of chemotherapy a first new ulceration
0,560,5 cm (ulcer 1) in the axilla of the right arm emerged. After
performing some de ´bridement, this lesion had healed 35 days later
and the patient was discharged from hospital. 275 days after
completion of chemotherapy the patient was readmitted with a
non ulcerated fluctuant nodule 1,561,5 cm (nodule 1) on the back
(Figure 1B), which was excised with primary skin closure one day
later. 409 days after completion of chemotherapy two more lesions
developed, a 1,561,5 cm nodule (nodule 2) on the thorax
(Figure 1C) and an ulcerated plaque 363 cm on the right
shoulder (ulcer 2) (Figure 1D). Both lesions were excised two days
after admission. From both lesions specimen taken were IS2404
PCR as well as AFB positive, whereas culture was negative. 28
days after the surgical intervention, the patient was discharged
from hospital. No further relapses were observed after 10 months
of follow-up (February 2011).
Patient 2, also a six year old boy, presented at the CDTUB with
a2 0 615 cm ulcerated lesion on the interior side of his right upper
leg and knee. Undermined edges as well as ‘cotton wool’
appearance of necrotic tissue at the center of the lesion were
characteristic for BU [42]. Clinical diagnosis was confirmed by
positive IS2404 PCR results and microscopic detection of AFB in
swab samples. Surgical de ´bridement was performed 29 days after
start of standard R/S chemotherapy followed 10 days later by skin
grafting. Twelve days after completion of antibiotic treatment, a
nodule (nodule 1) 262 cm; had emerged about 5 cm proximal of
the border of the primary lesion at the upper right leg and was
excised 7 days later. The initial lesion as well as the lesion at the
excision site had healed 39 days after completion of the antibiotic
treatment (i. e 57 days after skin grafting) and the patient was
discharged from hospital.
One week after discharge (46 days after completion of antibiotic
treatment) the patient was readmitted with a second nodule
(1,561,5 cm) located at the lower right leg about 15 cm distal of
the border of the primary lesion. Again eight days later (54 days
after completion of antibiotic treatment) a third nodule (nodule 3)
(362 cm) had emerged at the upper right leg located 5 cm
proximal of the initial wound. These two nodules were excised 93
days after completion of the antibiotic therapy. While AFB
staining, as well as IS2404 PCR confirmed the presence of M.
ulcerans, both nodules were culture negative.
After surgical excision and healing of the satellite lesions the
patient was discharged, but re-admitted 176 days after completion
of antibiotic treatment with a fourth nodule (nodule 4) 262c mo n
Figure 2. Histopathological presentation of secondary lesions. Histological sections (nodule 2 of patient 2) were stained either with Ziehl-
Neelsen (counterstain methylenblue; A, F, G) or with antibodies against cell surface or cytoplasmic markers (counterstain haematoxylin; B–E). A:
Overview over excised tissue specimen revealing typical BU pathology features like fat cell ghosts, necrosis, epidermal hyperplasia and AFB (region2 )
as well as a strong mixed infiltration typically observed in successfully treated BU lesions (region 1). B: CD14 staining of macrophages/monocytes; C:
CD3 staining of T-cells; D: Elastase staining of neutrophils. In the necrotic region 2 large numbers of elastase-positive neutrophilic debris (E) and small
clumps of AFB (F) with a beaded appearance (G) were observed.
doi:10.1371/journal.pntd.0001252.g002
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the patient was discharged 10 days later and no further relapses
were observed after 10 months of follow-up (February 2011).
Histopathological features of excised secondary lesions
Histopathological and immunohistochemical analyses were
performed with nodule 1, nodule 2 and ulcer 2 from patient 1,
and nodule 2 and 3 of patient 2 (Table 1). These lesions appeared
275 to 409 days and 46 to 54 days, respectively, after completion
of chemotherapy. Analysis yielded comparable results for all
specimens analyzed. Typical data are shown below.
Features characteristic for BU pathology, such as fat cell ghosts,
necrotic soft tissue, hemorrhages, and epidermal hyperplasia were
present in all specimens analyzed. As shown in Figure 2A, necrotic
areas were massively infiltrated with leucocytes, a feature, which is
characteristic for successfully treated lesions [20]. Immunohisto-
chemical analysis revealed mixed cellular infiltrations (Region 1)
composed of large numbers of CD14 positive macrophages/
monocytes (Figure 2B) and CD3 positive T-cells (Figure 2C). In
contrast, intact N-elastase positive neutrophils were rare
(Figure 2D). As described previously [20], some areas, such as
the AFB containing region 2 in Figure 2A contained N-elastase
positive debris (Figure 2E), which appears to represent remains of
an early wave of neutrophilic infiltration. ZN staining revealed
AFBs and globi like structures in the necrotic areas in the tissue
from nodule 1 of patient 1 and in nodules 2 and 3 of patient 2
(Figure 2F, G). AFBs had a ‘beaded’ appearance (Figure 2G),
which has been shown to be an indicator for loss of viability in the
case of M. leprae [43].
Clusters of CD20 positive B-cells, another hallmark of ectopic
lymphoid tissue developing in BU lesions after successful treatment
[20], were also found in the tissue specimens analyzed. These
clusters varied in size ranging from very large accumulations
forming a band throughout the whole tissue (Figure 3A) to small
dense B cell accumulations (Figure 3B) surrounded by CD14
positive macrophages/monocytes (Figure 3C) and few interspersed
CD3 positive T-cells (Figure 3D), mostly CD8 negative (Figure 3E),
mainly at the border of the dense B-cell cluster. Higher
magnifications confirmed the dense packaging of B-cells
(Figure 3F) and more dispersed distribution of other leucocytes
(Figure 3G–H).
In some parts of the lesions small uninfiltrated necrotic areas
surrounded by belts of leucocytes still remained. Immunohisto-
chemical analyses gave indications for sequential infiltration of
these areas by different types of leucocytes (Figure 4). Necrotic
areas were surrounded by an inner dense belt of CD14 positive
macrophages/monocytes (Figure 4A), which thus seem to
constitute the first line of infiltration after decline of cytotoxic
mycolactone levels. While a belt containing large numbers of CD3
positive T-cells representing a second line of infiltration were
found in direct neighborhood to the macrophages (Figure 4B),
intact N-elastase positive neutrophils (Figure 4C) and CD20
positive B-cells (Figure 4D) were comparatively rare in these
settings. However a strong staining of N-elastase positive
neutrophilic debris was observed inside the necrotic areas
(Figure 4C). Higher magnification revealed no intact cells in this
location (Figure 4C insert).
Discussion
In this report we describe the development of series of new skin
lesions in two BU patients 12 – 409 days after completion of
antibiotic treatment. The newly emerging nodules and ulcerations
were located either at some distance from the initial lesion at the
same extremity or at other body locations. Detection of M. ulcerans
DNA by IS2404 PCR, microscopic detection of AFBs and the
presence of histopathological features characteristic for BU
demonstrated that the new lesions were associated with M. ulcerans
infection. Degenerated appearance of the AFBs and the presence
of massive immune cell infiltrates in most parts of the lesions were
on the other hand characteristic for treated BU lesions [20].
Detailed immunohistochemical analyses showed that residual
necrotic areas were surrounded by an outer belt of T-lymphocytes
and an inner belt of macrophages/monocytes with appendices
reaching into the necrotic tissue. These belts of intact leucocytes
seem to reflect ongoing efforts of the immune system to resolve the
necrotic areas. In contrast, remains of neutrophils found inside the
necrotic areas seem to be leftovers of early acute neutrophilic
infiltration waves. These are also observed in early phases of M.
ulcerans infection in experimentally infected mice (MT Ruf et al.,
unpublished results). Apart from these residual necrotic regions,
the destroyed adipose and dermal connective tissue layers showed
angiogenesis and contained abundant leukocyte infiltrates. It is
thought that such chronic infiltrates can only develop once the
concentration of the cytopathic M. ulcerans macrolide toxin
mycolactone has diminished [20,44]. Imbedded in the diffuse
infiltrates, more structured leukocyte accumulations, such as B-cell
clusters indicative for humoral immune responses [45–47] and first
granulomas were found. In BU granulomas may function
primarily as a place for antigen presentation and adaptive immune
response, rather than for sequestration of the mycobacteria [20].
Recently O’Brien et al have described the occurrence of
paradoxical reaction in two Australian BU patients during R/S
treatment of BU [41]. After a first clinical improvement worsening
of the clinical appearance occurred. For one patient incomplete
excised wound margins showed paradoxical reaction whereas for
the other patient a more distant secondary lesion opened, before
end of treatment was reached. Worsening of lesions motivated a
change in the treatment regimen and additional surgery. After
detailed evaluation, data have been interpreted as immune-
mediated reactions rather than treatment failures, as it has been
shown that antibiotic therapy for M. ulcerans leads to a reversal of
local immunosuppression [20,41,48]. The observed vigorous local
immune responses are most likely caused by bacterial antigens and
immunostimulators released from the killed mycobacteria. Similar
paradoxical reactions have been well described for M. tuberculosis,
M. leprae and in particular in immunocompromised HIV patients
who commence HAART [49–52]. In tuberculosis an elevation of
the TNF-a level, stimulated by lipoarabinomanan and other
lipopolysaccharides present in the cell wall, has been postulated as
an initial step in the development of paradoxical reaction [53,54].
Limited surgical excision may help to resolve paradoxical reactions
by reducing the burden of mycobacterial antigens and in some
clinical settings corticosteroids have been used for down regulation
of immune responses [55–58].
Figure 3. Presence of B-cell clusters in the secondary lesions. A: Band of CD20 positive B-cells in sections of ulcer 2 of patient 1. B–E: serial
sections of nodule 3 of patient 2 with a small dense cluster of CD20 positive B-cells (B) surrounded by CD14 positive macrophages/monocytes (C) and
few interspersed CD3 positive T-cells (D) from which the majority was CD8 negative (E). Higher magnification (F–I) revealed a very dense package of
the B-cells.
doi:10.1371/journal.pntd.0001252.g003
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developed at prolonged periods of time after completion of
antibiotic treatment. These lesions may represent secondary M.
ulcerans infection foci that were already present without clinical
signs and symptoms during antibiotic treatment and development
of new lesions may be the consequence of delayed paradoxical
reactions. However, in particular the lesions that appeared more
than one year after completion of antibiotic treatment may also
have been associated with new infection foci caused by new M.
ulcerans infections or by mycobacteria that had survived the eight
week course of R/S treatment [28,29]. These may have been
resolved by immune responses primed by the successful treatment
of the primary lesion. If this is the case, detailed analysis of
immune responses in more patients developing such secondary
lesions may provide important insights into immune protection
against M. ulcerans and support vaccine design [59].
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